Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On Eve Of European Launch, Abbott’s Xience V Outperforms Taxus

This article was originally published in The Gray Sheet

Executive Summary

Abbott is trumpeting the latest findings about its Xience V drug-eluting stent in preparation for next month's European launch

You may also be interested in...



No Surprise, ZoMaxx TCT Data Not Impressive; Should Medtronic Worry?

Abbott's ZoMaxx drug-eluting stent (DES) did not measure up to Boston Scientific's Taxus in nine-month data reported Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C

No Surprise, ZoMaxx TCT Data Not Impressive; Should Medtronic Worry?

Abbott's ZoMaxx drug-eluting stent (DES) did not measure up to Boston Scientific's Taxus in nine-month data reported Oct. 23 at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C

Abbott launches updated stroke device

Firm announces CE mark approval and European launch of its Emboshield PRO embolic protection system on Sept. 13. The next-generation device is more radiopaque than its predecessor, providing better X-ray visibility, Abbott says. Its small size and enhanced profile position the device as a new option for tortuous vessels, according to the firm. Separately, on Sept. 12 the firm reported an expansion of its manufacturing facility in Ireland to ramp up production of the Xience V drug-eluting stent, expected to debut in October (1"The Gray Sheet" Sept. 11, 2006, p. 5)...

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel